You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
阿斯利康(AZN.US)Imfinzi組合可降低膽道癌症患者24%的死亡風險
格隆匯 09-12 18:26
格隆匯9月12日丨英國製藥巨頭阿斯利康(AZN.US)表示,在一項名為TOPAZ-1的三期臨牀試驗中,Imfinzi聯合化療(吉西他濱+順鉑)對晚期膽道癌(BTC)患者顯示了臨牀意義和持久的總生存期(OS)受益。根據更新的數據,Imfinzi聯合化療(吉西他濱+順鉑)在額外的6.5個月的隨訪後顯示出更好的臨牀療效,與單純化療相比,死亡風險降低了24%。更新的中位OS為12.9個月,而化療組為11.3個月。公司補充説,使用Imfinzi組合的患者中有23.6%的人預計活到2年,而單獨使用化療的患者只有11.5%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account